JP2023526500A5 - - Google Patents

Info

Publication number
JP2023526500A5
JP2023526500A5 JP2022571167A JP2022571167A JP2023526500A5 JP 2023526500 A5 JP2023526500 A5 JP 2023526500A5 JP 2022571167 A JP2022571167 A JP 2022571167A JP 2022571167 A JP2022571167 A JP 2022571167A JP 2023526500 A5 JP2023526500 A5 JP 2023526500A5
Authority
JP
Japan
Application number
JP2022571167A
Other languages
Japanese (ja)
Other versions
JP2023526500A (ja
JPWO2021236809A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033222 external-priority patent/WO2021236809A2/en
Publication of JP2023526500A publication Critical patent/JP2023526500A/ja
Publication of JP2023526500A5 publication Critical patent/JP2023526500A5/ja
Publication of JPWO2021236809A5 publication Critical patent/JPWO2021236809A5/ja
Pending legal-status Critical Current

Links

JP2022571167A 2020-05-19 2021-05-19 アルツハイマー病の処置のためのマルチエピトープワクチン Pending JP2023526500A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063027150P 2020-05-19 2020-05-19
US63/027,150 2020-05-19
US202063062903P 2020-08-07 2020-08-07
US63/062,903 2020-08-07
US202163140917P 2021-01-24 2021-01-24
US63/140,917 2021-01-24
PCT/US2021/033222 WO2021236809A2 (en) 2020-05-19 2021-05-19 Multi-epitope vaccine for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2023526500A JP2023526500A (ja) 2023-06-21
JP2023526500A5 true JP2023526500A5 (https=) 2024-05-28
JPWO2021236809A5 JPWO2021236809A5 (https=) 2024-05-28

Family

ID=78708070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571167A Pending JP2023526500A (ja) 2020-05-19 2021-05-19 アルツハイマー病の処置のためのマルチエピトープワクチン

Country Status (15)

Country Link
US (6) US20230183304A1 (https=)
EP (1) EP4153210A4 (https=)
JP (1) JP2023526500A (https=)
KR (1) KR20230037501A (https=)
CN (1) CN115867304A (https=)
AU (1) AU2021276401A1 (https=)
BR (1) BR112022023366A2 (https=)
CA (1) CA3178760A1 (https=)
CL (2) CL2022003253A1 (https=)
IL (1) IL298215A (https=)
JO (1) JOP20220316A1 (https=)
MX (1) MX2022014453A (https=)
PH (1) PH12022553234A1 (https=)
TW (1) TW202208409A (https=)
WO (1) WO2021236809A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1952110T3 (en) 2005-11-08 2015-08-10 Temptime Corp Combined frost indicators
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN116724046A (zh) * 2020-09-17 2023-09-08 欧萨尔普罗席纳有限公司 用于治疗阿尔茨海默病之β淀粉样蛋白疫苗
IL301262A (en) * 2020-09-18 2023-05-01 Othair Prothena Ltd Multiepitope vaccine for the treatment of alzheimer's disease
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CU20230023A7 (es) 2023-05-12 2024-12-09 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer
CN120919292A (zh) * 2025-08-04 2025-11-11 首都医科大学宣武医院 用于预防或治疗阿尔茨海默病的Aβ-Tau多表位疫苗及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5840838A (en) 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
WO2004087733A2 (en) 2003-03-28 2004-10-14 New York University Prevention and treatment of alzheimer amyloid deposition
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
ATE524487T1 (de) * 2007-01-11 2011-09-15 Univ Ramot Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9738709B2 (en) * 2011-10-21 2017-08-22 Ohio State Innovation Foundation Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
CA2885924C (en) * 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA3003483C (en) 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
EP3609505A4 (en) 2017-04-13 2021-04-28 Adjuvance Technologies, Inc. TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES
CN110730666A (zh) 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
BR112019026707A2 (pt) 2017-06-16 2020-06-30 United Neuroscience imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias
WO2019070480A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
WO2019070813A2 (en) * 2017-10-03 2019-04-11 The Trustees Of Columbia University In The City Of New York USE OF PEPTIDES AS BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION AND TREATMENT OF A NEUROLOGICAL DISORDER
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
KR20230080397A (ko) * 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신

Similar Documents

Publication Publication Date Title
JP2023526500A5 (https=)
CN306757827S (https=)
CN306738752S (https=)
CN305572243S (https=)
CN305584395S (https=)
CN305614631S (https=)
CN305646299S (https=)
CN305648174S (https=)
CN305650658S (https=)
CN305652490S (https=)
CN305654235S (https=)
CN305655111S (https=)
CN305675218S (https=)
CN305677435S (https=)
CN305677921S (https=)
CN306457196S (https=)
CN306457348S (https=)
CN306458457S (https=)
CN306462613S (https=)
CN306674110S (https=)
CN306720719S (https=)
CN306727426S (https=)
CN306728133S (https=)
CN306728669S (https=)
CN306729962S (https=)